AKRX

U.S. Drug Spending Increases Most in 13 Years to $373.9 Billion – Bloomberg Business

by

Often times it seems that the news, particularly economic news is out of step with the price action in the stock market.  This headline is not. No wonder healthcare is the best performing sector in the market and likely to continue to outperform with the huge demographic tailwinds behind it. U.S. spending on prescription drugs saw the largest increase since 2001, with the nation’s pharmacy bill rising to $373.9 billion last year as new treatments came to market and manufacturers increased prices on old ones.“Last year’s $43 billion growth in spending on medicines was the highest ever,” said Murray Aitken, … Read more

Akorn, Inc $AKRX Catalysts are looming

by

Specialty pharmaceuticals, biotech, and even big cap pharma are exhibiting great relative price performance.  One that we just purchased Monday, Akorn, Inc. (AKRX)  on a sharp pullback based on recent news that the 10k would be delayed, a director just resigned, and an analyst at Sterne Agee just warned of competition to the company’s biggest seller, an eczema psoriasis cream that is coming to the market from Actavis.  So what’s there to like?  Plenty according to Merrill Lynch analyst, Sumant Kulkarni.  He published a research note on 3-10-15 “AKRX stock is down 15% today mainly on last night’s news that competition has entered … Read more